预约演示
GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition
并购引进/卖出抗体药物偶联物
GSK has announced that it will be acquiring Aiolos Bio for approximately $1.4bn, marking a notable boost to the company’s respiratory and inflammatory disease pipeline.
GSK deal grants GSK access to Aiolos’ AIO-00Aiolos Bioacting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody respiratory and inflammatory diseaselopment to treat asthma, with the potential for additional indications including chronic rhinosinusitis with nasal polyps.
Targeting the TSGSKpathway addresses aAIO-001iver of the inflammatthymic stromal lymphopoietin (TSLP)inflammatory diseases, GSK outlined, adding that early studies of AIO-001 asthmahown “initial safety, tolerability, pharmacokinetics and bchronic rhinosinusitis both nasal polypsicipants and asthma patients.
There are an estimated 315 million patients living with asthma worldwide.
Tony Wood, chief scientific officer at GSK, said: “Addinasthma001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed.”
Under the terms of the agreement, GSK wGSK pay Aiolos $1bnAIO-001t and up to $400m in certain success-based regulatoryTSLPestone payments. GSK will also be responsible for success-based milestone payments and tiered royalties owed to asthmai Pharma, whichlow T2 inflammationo Aiolos.
“By uniting with GSK… we’re confident thatAiolosn rapidly advance this therapy in the hopes of significantly reducing the treatment burdenanti-TSLP monoclonal antibodyAIO-001
The acquisition cGSKs less than one month after GSK entered into an agreement to exclusively licence Hansoh Pharma's clinical-stage antibody-drug conjugate (ADCs) in a deal worth more than $1.7bn.
HS-20093 is a novel B7-H3-targeted ADC being devGSKped for a range of solid tumour types, including lHansoh Pharmaarcoma, and head and neck cancers.
HS-20093idate has alB7-H3-targeted ADC clinical activity in small cellsolid tumour, non-small cell llung canceransarcomama, achead and neck cancersthe early-stage ARTEMIS-001 trial.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。